Bio-Path Holdings Reveals Interim Results From Phase 2 Study Of prexigebersen In Combination With decitabine And venetoclax For Treatment Of Acute Myeloid Leukemia
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings presented interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for treating acute myeloid leukemia at the 2024 European Hematology Association Congress. The data showed that prexigebersen is well-tolerated and has demonstrated compelling efficacy in both newly diagnosed and refractory/relapsed AML patients.
June 14, 2024 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bio-Path Holdings presented promising interim results from its Phase 2 study of prexigebersen for AML treatment, showing the drug is well-tolerated and effective in both newly diagnosed and refractory/relapsed patients.
The positive interim results from the Phase 2 study of prexigebersen, showing both tolerability and efficacy, are likely to boost investor confidence in Bio-Path Holdings. This could lead to a short-term increase in BPTH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100